Bergenbio ASA
OTC:BRRGF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bergenbio ASA
OTC:BRRGF
|
NO |
|
M
|
Max Sight Group Holdings Ltd
HKEX:8483
|
HK |
|
NPK OVK PAO
MOEX:UWGN
|
RU |
|
Y
|
Yijia Group Corp
OTC:YJGJ
|
HK |
|
Carter Bank and Trust
NASDAQ:CARE
|
US |
|
S
|
Samfine Creation Holdings Group Ltd
NASDAQ:SFHG
|
HK |
|
Move Logistics Group Ltd
NZX:MOV
|
NZ |
|
Amsc ASA
OSE:AMSC
|
NO |
|
L
|
La Jolla Pharmaceutical Co
F:LJPP
|
US |
Bergenbio ASA
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
